{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,5]],"date-time":"2026-09-05T01:08:43Z","timestamp":1788570523982,"version":"build-2803163510"},"reference-count":28,"publisher":"Elsevier BV","issue":"18","license":[{"start":{"date-parts":[[2015,4,1]],"date-time":"2015-04-01T00:00:00Z","timestamp":1427846400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2015,4]]},"DOI":"10.1016\/j.vaccine.2015.03.017","type":"journal-article","created":{"date-parts":[[2015,3,25]],"date-time":"2015-03-25T22:21:01Z","timestamp":1427322061000},"page":"2132-2140","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":12,"title":["M-M-R\u00aeII manufactured using recombinant human albumin (rHA) and M-M-R\u00aeII manufactured using human serum albumin (HSA) exhibit similar safety and immunogenicity profiles when administered as a 2-dose regimen to healthy children"],"prefix":"10.1016","volume":"33","author":[{"given":"Richard T.","family":"Wiedmann","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keith S.","family":"Reisinger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan","family":"Hartzel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edgardo","family":"Malacaman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shelly D.","family":"Senders","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katherine E.D.","family":"Giacoletti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric","family":"Shaw","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barbara J.","family":"Kuter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Florian","family":"Sch\u00f6del","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luwy K.","family":"Musey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"June (25)","key":"10.1016\/j.vaccine.2015.03.017_bib0145","first-page":"ND-339","article-title":"Notifiable diseases and mortality tables, United States 2012","volume":"61","author":"Centers for Disease Control and Prevention","year":"2012","journal-title":"MMWR"},{"key":"10.1016\/j.vaccine.2015.03.017_bib0150","unstructured":"U.S. Package Circular: M-M-R\u00aeII (measles, mumps, and rubella virus vaccine live); 2014, February."},{"issue":"RR-8","key":"10.1016\/j.vaccine.2015.03.017_bib0155","first-page":"1","article-title":"Measles, mumps, and rubella \u2013 vaccine use and strategies for elimination of measles, rubella, and congenital rubella syndrome and control of mumps: recommendations of the Advisory Committee on Immunization Practices (ACIP)","volume":"47","author":"Centers for Disease Control and Prevention","year":"1998","journal-title":"MMWR"},{"key":"10.1016\/j.vaccine.2015.03.017_bib0160","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1542\/peds.100.5.767","article-title":"MMR2 immunization at 4 to 5 years and 10 to 12 years of age: a comparison of adverse clinical events after immunization in the vaccine safety datalink project","volume":"100","author":"Davis","year":"1997","journal-title":"Pediatrics"},{"issue":"53","key":"10.1016\/j.vaccine.2015.03.017_bib0165","first-page":"1","article-title":"Summary of notifiable diseases, United States 1998","volume":"47","author":"Centers for Disease Control and Prevention","year":"1999","journal-title":"MMWR"},{"issue":"21","key":"10.1016\/j.vaccine.2015.03.017_bib0170","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.1056\/NEJM199411243312101","article-title":"The elimination of indigenous measles, mumps, and rubella from Finland by a 12-year, two-dose vaccination program","volume":"331","author":"Peltola","year":"1994","journal-title":"N Engl J Med"},{"key":"10.1016\/j.vaccine.2015.03.017_bib0175","doi-asserted-by":"crossref","first-page":"1264","DOI":"10.1136\/bmj.295.6608.1264","article-title":"Swedish experience of two dose vaccination programme aiming at eliminating measles, mumps, and rubella","volume":"295","author":"B\u00f6ttiger","year":"1987","journal-title":"Br Med J"},{"key":"10.1016\/j.vaccine.2015.03.017_bib0180","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1128\/AEM.25.1.49-54.1973","article-title":"Survival of animal tissue cells in primary culture in the absence of serum","volume":"25","author":"Orr","year":"1973","journal-title":"Appl Microbiol"},{"key":"10.1016\/j.vaccine.2015.03.017_bib0185","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1177\/0091270004269646","article-title":"Phase I comparability of recombinant human albumin and human serum albumin","volume":"45","author":"Bosse","year":"2005","journal-title":"J Clin Pharmacol"},{"key":"10.1016\/j.vaccine.2015.03.017_bib0190","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.biologicals.2005.08.021","article-title":"Summary of recombinant human serum albumin development","volume":"34","author":"Kobayashi","year":"2006","journal-title":"Biologicals"},{"key":"10.1016\/j.vaccine.2015.03.017_bib0195","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1111\/j.1470-8744.1989.tb00060.x","article-title":"Production of recombinant human serum albumin from Saccharomyces cerevisiae","volume":"11","author":"Quirk","year":"1989","journal-title":"Biotechnol Appl Biochem"},{"key":"10.1016\/j.vaccine.2015.03.017_bib0200","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1111\/j.1470-8744.1996.tb00397.x","article-title":"Comparative studies of recombinant human albumin and human serum albumin derived by blood fractionation","volume":"24","author":"Dodsworth","year":"1996","journal-title":"Biotechnol Appl Biochem"},{"key":"10.1016\/j.vaccine.2015.03.017_bib0205","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1128\/JCM.33.4.811-815.1995","article-title":"Comparison of commercial enzyme immunoassay kits with plaque reduction neutralization test for detection of measles virus antibody","volume":"33","author":"Ratnam","year":"1995","journal-title":"J Clin Microbiol"},{"key":"10.1016\/j.vaccine.2015.03.017_bib0210","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1002\/sim.4780040211","article-title":"Comparative analysis of two rates","volume":"4","author":"Miettinen","year":"1985","journal-title":"Stat Med"},{"key":"10.1016\/j.vaccine.2015.03.017_bib0215","series-title":"Modelling binary data","author":"Collett","year":"1999"},{"issue":"5","key":"10.1016\/j.vaccine.2015.03.017_bib0220","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1097\/00006454-199305000-00037","article-title":"Pediatric experience with recombinant hepatitis B vaccines and relevant safety and immunogenicity studies","volume":"12","author":"Greenberg","year":"1993","journal-title":"Pediatr Infect Dis J"},{"key":"10.1016\/j.vaccine.2015.03.017_bib0225","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/S0264-410X(99)00179-6","article-title":"Over a decade of experience with a yeast recombinant hepatitis B vaccine","volume":"18","author":"Assad","year":"2000","journal-title":"Vaccine"},{"issue":"13","key":"10.1016\/j.vaccine.2015.03.017_bib0230","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1056\/NEJM199703273361307","article-title":"Current concepts: erythropoietin therapy","volume":"336","author":"Goodnough","year":"1997","journal-title":"N Engl J Med"},{"issue":"7","key":"10.1016\/j.vaccine.2015.03.017_bib0235","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1056\/NEJMoa011931","article-title":"Pure red-cell aplasia and antierythropoietin antibodies in patients treated with recombinant erythropoietin","volume":"346","author":"Casadevall","year":"2002","journal-title":"N Engl J Med"},{"key":"10.1016\/j.vaccine.2015.03.017_bib0240","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1046\/j.1365-2516.1999.00191.x","article-title":"Human recombinant DNA-derived antihaemophilic factor (factor VIII) in the treatment of haemophilia A: conclusions of a 5-year study of home therapy","volume":"5","author":"Seremetis","year":"1999","journal-title":"Haemophilia"},{"issue":"Suppl. 2","key":"10.1016\/j.vaccine.2015.03.017_bib0245","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1046\/j.1351-8216.2001.00131.x","article-title":"European data of a clinical trial with a sucrose formulated recombinant factor VIII in previously treated haemophilia A patients","volume":"8","author":"Rothschild","year":"2002","journal-title":"Haemophilia"},{"key":"10.1016\/j.vaccine.2015.03.017_bib0250","unstructured":"U.S. Package Circular: Synagis\u00ae (Palivizumab) injection for intramuscular use; 2012, April."},{"issue":"20","key":"10.1016\/j.vaccine.2015.03.017_bib0255","doi-asserted-by":"crossref","first-page":"1584","DOI":"10.1056\/NEJM200205163462015","article-title":"Pure red-cell aplasia and recombinant erythropoietin","volume":"346","author":"Gershon","year":"2002","journal-title":"N Engl J Med"},{"issue":"8","key":"10.1016\/j.vaccine.2015.03.017_bib0260","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1097\/01.inf.0000172901.29621.e9","article-title":"Dose\u2013response study of a quadrivalent measles, mumps, rubella and varicella vaccine in healthy children","volume":"24","author":"Shinefield","year":"2005","journal-title":"Pediatr Infect Dis J"},{"issue":"7","key":"10.1016\/j.vaccine.2015.03.017_bib0265","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1097\/01.inf.0000220209.35074.0b","article-title":"The safety and immunogenicity of a quadrivalent measles, mumps, rubella and varicella vaccine in healthy children","volume":"25","author":"Lieberman","year":"2005","journal-title":"Pediatr Infect Dis J"},{"issue":"4","key":"10.1016\/j.vaccine.2015.03.017_bib0270","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1097\/01.inf.0000207857.10947.1f","article-title":"Safety and immunogenicity of a measles, mumps, rubella and varicella vaccine given with combined haemophilus influenza type b conjugate\/hepatitis B vaccines and combined diphtheria-tetanus-acellular pertussis vaccines","volume":"25","author":"Shinefield","year":"2006","journal-title":"Pediatr Infect Dis J"},{"issue":"2","key":"10.1016\/j.vaccine.2015.03.017_bib0275","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1542\/peds.2005-0092","article-title":"A combination measles, mumps, rubella, and varicella vaccine (ProQuad) given to 4- to 6-year-old healthy children vaccinated previously with M-M-RII and Varivax","volume":"117","author":"Reisinger","year":"2006","journal-title":"Pediatrics"},{"key":"10.1016\/j.vaccine.2015.03.017_bib0280","doi-asserted-by":"crossref","first-page":"6918","DOI":"10.1016\/j.vaccine.2012.08.057","article-title":"Measles, mumps, and rubella virus vaccine (M-M-R\u2122II): a review of 32 years of clinical and postmarketing experience","volume":"30","author":"Lievano","year":"2012","journal-title":"Vaccine"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X15003059?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X15003059?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,6,8]],"date-time":"2024-06-08T01:21:02Z","timestamp":1717809662000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X15003059"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,4]]},"references-count":28,"journal-issue":{"issue":"18","published-print":{"date-parts":[[2015,4]]}},"alternative-id":["S0264410X15003059"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2015.03.017","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2015,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"M-M-R\u00aeII manufactured using recombinant human albumin (rHA) and M-M-R\u00aeII manufactured using human serum albumin (HSA) exhibit similar safety and immunogenicity profiles when administered as a 2-dose regimen to healthy children","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2015.03.017","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}